On this page
What supports reinstatement of an IND terminated for immediate and substantial danger?
For immediate termination under §312.44(d), organize additional submissions around evidence that eliminates the danger identified by FDA. Tie each finding to the investigated cause, corrective action, supporting results and proposed study controls. Request the appropriate agency action and preserve the restriction; submission or elapsed time alone does not reinstate the IND.
Before you begin
Especially immediate termination under 21 CFR 312.44(d), where the regulation provides for reinstatement on additional submissions eliminating the danger. Establish the actual order and authority first.
What you will prepare: A traceable corrective evidence package and request for agency action, with no assumed permission to resume.
Read the termination order as the starting requirement
Retrieve the complete FDA notice, date, issuing authority, stated grounds and procedural history. Section 312.44 distinguishes ordinary termination procedures from immediate termination for an immediate and substantial danger. Under paragraph (d), an IND so terminated is subject to reinstatement by the Director on additional submissions eliminating that danger.
Do not copy the 30-day inactive-IND resumption rule from §312.45. A new submission and passage of time alone do not reinstate a terminated IND. If the file actually shows a clinical hold or inactive status, use the corresponding process instead.
Write an evidence-to-finding response
Prepare a matrix with the agency finding, underlying cause established by investigation, corrective action, objective evidence, impact on the proposed study, remaining uncertainty and exact dossier reference. Include revised protocols, risk controls, manufacturing information or other supporting reports as relevant to the actual reason for termination. A promise to improve procedures is not equivalent to evidence eliminating the identified danger.
The cover request should identify the IND and order, state the requested reinstatement, summarize how the additional submissions address each ground and identify the responsible contact. Have the appropriate clinical, safety, quality and regulatory specialists review whether the evidence supports the request. Maintain the current restriction until the requisite agency action and other study-start requirements are satisfied.
Worked check: corrective SOP without effectiveness evidence
Fictional exercise: termination followed unreliable dose preparation. The proposed response contains a revised SOP but no evidence that the process now controls dose accurately. The author must identify that missing evidence instead of declaring the danger eliminated. Route the technical work to its owner and preserve the open item.
Change the starting record to an ordinary inactive-status letter: the reinstatement guide is no longer the appropriate status route. Unknown order type remains undetermined until the actual agency record is obtained.
Distinguish an implemented correction from demonstrated control
Use the termination notice to build a review table. The table below illustrates the reasoning for a fictional dose-preparation problem; it does not prescribe a validation protocol or the evidence FDA will accept in a real case.
| Review question | Weak entry | More useful entry |
|---|---|---|
| What caused the danger? | “Operator error” | Investigation-supported mechanism and affected operations |
| What changed? | “New SOP issued” | Controlled procedure, equipment or training changes tied to that mechanism |
| What demonstrates control? | “Staff will comply” | Relevant results, acceptance criteria and unresolved deviations |
| Does the evidence fit the proposed study? | “Same drug as before” | Comparison of dose preparation, setting, personnel and protocol conditions |
| What remains uncertain? | “None” by default | Explicit evidence gaps and their effect on the request |
Follow each conclusion to an exact report, dataset or controlled record. A reviewer should be able to distinguish work proposed, work implemented and effectiveness demonstrated. If the investigation has not established a cause, say so and identify the missing work. A confident narrative cannot supply that evidence.
Scope exercise: a correction was evaluated in a central pharmacy, but the restart proposal includes preparation at individual sites. The central results do not, by themselves, demonstrate control under the different site conditions. Ask the technical owners to assess that difference and support the proposed scope. Narrowing a sentence without addressing the changed conditions would leave the underlying question unanswered.
The reinstatement request should summarize the response and direct FDA to the substantive submissions. Keep the agency’s decision separate from the team’s readiness recommendation. For other termination grounds or disputed procedures, use the actual notice and applicable process; do not present paragraph (d) as a universal restart mechanism. Return to the status-change map if the order is unavailable, and compare inactive-IND reactivation only after the starting state is established.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is reinstatement the same as reactivation of an inactive IND?
No. Section 312.45 addresses inactive INDs, while §312.44(d) provides for reinstatement after immediate termination based on additional submissions eliminating the identified danger. Establish the actual FDA action before choosing the procedure. Similar business intentions to resume work do not make the regulatory starting states interchangeable.
Does FDA’s receipt of a reinstatement request start a 30-day permission clock?
No inactive-IND permission clock should be imported into this process. For an IND immediately terminated under §312.44(d), the provision calls for reinstatement by the Director on the required evidentiary basis. Receipt of a submission and a team’s proposed start date do not establish that decision.
Is issuing a corrective SOP enough to show the danger has been eliminated?
Not by itself. An issued SOP shows that a document changed. The request needs evidence addressing the danger identified in the termination action. Explain the investigated cause, implemented controls, relevant results and their applicability to the proposed investigation; preserve unresolved gaps rather than declaring them closed.
Can the sponsor simply continue investigations while FDA reviews reinstatement?
No. Section 312.44 requires the sponsor to end investigations under a terminated IND and address unused drug supplies. A pending reinstatement request does not erase that status. Establish the requisite agency disposition and other applicable study conditions before treating the proposed investigation as authorized to resume.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 312: IND responsibilities and status ↗Current part reopened September 22, 2026; relevant provisions identified in each section. Regulatory requirements, not a marketing-application rule.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.5.4. A heading identifies placement, not mandatory applicability.